We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
(Approval lapsed) VYVANSE lisdexamfetamine dimesylate capsules 60mg (USA)
Section 19A approved medicine
(Approval lapsed) VYVANSE lisdexamfetamine dimesylate capsules 60mg (USA)
Section 19A approval holder
Medsurge Healthcare Pty Ltd ABN 92 124 728 892
Phone
1300 788 261
Approved until
Status
Expired
Medicines in short supply/unavailable
VYVANSE lisdexamfetamine dimesilate 60 mg capsules bottle - ARTG 284021
Indication(s)
Attention Deficit Hyperactivity Disorder (ADHD)
Indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Treatment should be commenced by a specialist. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before 12 years of age.
Binge Eating Disorder (BED)
Indicated for the treatment of moderate to severe BED in adults when non-pharmacological treatment is unsuccessful or unavailable. Treatment should be commenced and managed by a psychiatrist.
Images
